EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1

Yijing Zhang iD, Han Gao, Aiwen Tang, Haiwen Lyu, Zongmin Fan, Jiahui Guo, Yuzhi Wang, Hairong Yi, Qihao Pan, Haidan Luo, Baifu Qin, Boyu Zhang und 3 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202510210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yijing Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Deoxycytidine, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer with poor prognosis. COP9 signalosome subunit 6 (CSN6), a key regulator of different E3 ubiquitin ligases, plays oncogenic roles in various cancers. However, its function in PDAC remains elusive. Here, this demonstrates that human PDAC tumors expressing high levels of CSN6 present with poor prognosis and gemcitabine resistance. Conditional knockout (KO) of CSN6 hinders tumor formation in a KPP spontaneous PDAC mouse model. Proteomic analysis indicates that CSN6 promotes ribosome biogenesis by activating rDNA transcription and protein synthesis. Mechanistically, CSN6 antagonizes DDB1‐CUL4 associated factor 1 (DCAF1)‐mediated ubiquitination of Nucleophosmin (NPM1), thereby promoting NPM1‐orchestrated ribosome biogenesis. In line with CSN6‐mediated gemcitabine resistance, CSN6‐NPM1 axis enhances ribosome biogenesis, thereby promoting translation of gemcitabine resistance genes, including Cytidine deaminase (CDA), Ribonucleotide reductase subunit M1/2 (RRM1/2). Significantly, combining gemcitabine with NPM1 inhibitor NSC348884 synergistically suppresses CSN6‐high pancreatic cancer xenografts. Clinically, CSN6 expression positively correlates with NPM1 in PDAC tissues, and their concurrent high expression is significantly associated with poor clinical outcomes. This study characterizes CSN6 as an oncogenic protein that promotes NPM1 stabilization by interacting with DCAF1, thereby enhancing ribosome biogenesis and cellular resistance to gemcitabine in PDAC. NPM1 may serve as a therapeutic target for CSN6 high PDAC that exhibits gemcitabine drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDeoxycytidineDrug Resistance, NeoplasmCarcinoma, Pancreatic DuctalCOP9 Signalosome ComplexNuclear ProteinsAdaptor Proteins, Signal TransducingGemcitabineNucleophosminAnimalsHumansMiceUbiquitinationCell Line, TumorDisease Progression

Stichwörter der Autor:innen

CSN6DCAF1NPM1PDACgemcitabine resistance

Substanzen

GemcitabineNucleophosminDeoxycytidineNPM1 protein, humanCOP9 Signalosome ComplexNuclear ProteinsAdaptor Proteins, Signal TransducingNpm1 protein, mouse

Autor:innen und Institutionen

  • Guangdong Provincial Key laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Guangdong Institute of Gastroenterology, Guangzhou, 510655, China.
  • Department of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
  • Institute of Molecular and Medical Virology, School of Medicine, Jinan University, Guangzhou, Guangdong Province, 510632, China.

ORCID-Profile: Yijing Zhang, Mong-Hong Lee

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Project
  • Key Technologies Research and Development Program

Zitieren

APA

Zhang, Y., Gao, H., Tang, A., Lyu, H., Fan, Z., Guo, J., Wang, Y., Yi, H., Pan, Q., Luo, H., Qin, B., Zhang, B., Meng, X., Liu, Q., & Lee, M. H. (2026). CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1. Advanced Science. https://doi.org/10.1002/advs.202510210

Vancouver

Zhang Y, Gao H, Tang A, Lyu H, Fan Z, Guo J, et al. CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1. Advanced Science. 2026. doi:10.1002/advs.202510210

BibTeX
@article{Zhang2026,
  author = {Zhang, Yijing and Gao, Han and Tang, Aiwen and Lyu, Haiwen and Fan, Zongmin and Guo, Jiahui and Wang, Yuzhi and Yi, Hairong and Pan, Qihao and Luo, Haidan and Qin, Baifu and Zhang, Boyu and Meng, Xiangqi and Liu, Qingxin and Lee, Mong-Hong},
  title = {CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202510210}
}
Kostenlos starten →